Teva Pharmaceuticals

TEVA

Market cap $39.9B

Teva is pivoting from generic-drug maker to major pharmaceutical company. Even after more than doubling in price over the past year, shares have more room to run, thanks to the company's robust pipeline.

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 12, 2026. The presentation will begin at 9:20 A.M. Pacific Time (12:20 P.M. Eastern Time).

Teva beats Q1 earnings and revenue estimates as Austedo, Ajovy and Uzedy fuel growth, lifting shares despite weaker generics performance.

TEL AVIV, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2025 Healthy Future Report, outlining performance against its sustainability targets, which are focused on the issues most relevant to its business, patients and the planet. Teva surpassed all 2025 targets associated with its sustainability-linked bonds—totaling approximately $7.5 billion across its 2021 and 2023 issuances. These commitments reflect progress in areas such as climate action, health equity and access to medicines, linking financial and sustainability performance.

Teva Pharmaceutical Industries Limited (TEVA) Q1 2026 Earnings Call Transcript

Teva Pharmaceuticals CEO Richard Francis joins 'Money Movers' to discuss the company's latest acquisition of Emalex Biosciences, their latest drug offerings, and more.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), on Wednesday agreed to acquire Emalex Biosciences, including its lead asset, ecopipam.

While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teva stock jumped early Wednesday on a strong first-quarter report, as its key brands outperformed generics in the U.S.